Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

UNKNOWN 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Nasopharyngeal Carcinoma 18Esophageal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Stomach Neoplasms 4Neoplasms 3Colorectal Neoplasms 3Recurrence 2Pancreatic cancer, adult 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Diffuse Intrinsic Pontine Glioma 2Carcinoma 2Adenocarcinoma 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Anal Canal 1Solid Tumors 1Solid Tumor 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Nasopharyngeal Diseases 1NSCLC 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 71apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × nimotuzumab × Clear all
NCT01813253 2018-03-26

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Kuhnil Pharmaceutical Co., Ltd.

Phase 3 Terminated
400 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03400592 2018-01-17

NIEGA

Peking University

Phase 2 Unknown
55 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02370849 2015-02-25

Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma

ChineseAMS

Phase 2 Completed
2 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01180166 2013-09-19

Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer

ChineseAMS

Phase 2 Unknown
30 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡